Sandra Tomek
Impact in
- Oncology top 10%
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
- Cancer Treatment and Pharmacology
Papers in
- Oncology 8
- Cancer Treatment and Pharmacology 4
- HER2/EGFR in Cancer Research 4
- Co-authors
- Christoph ZielinskiChristian ManegoldMichael KrainerPeter HorakDietmar PilsWolfgang J. KöstlerIngrid PribillGünther Steger
In The Last Decade
Sandra Tomek
17 papers receiving 580 citations
Peers
Comparison fields: 5 of 60
- Oncology 263
- Cancer Research 113
- Radiology, Nuclear Medicine and Imaging 171
- Pulmonary and Respiratory Medicine 189
- Immunology and Allergy 30
Countries citing papers authored by Sandra Tomek
This map shows the geographic impact of Sandra Tomek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra Tomek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra Tomek more than expected).
Fields of papers citing papers by Sandra Tomek
This network shows the impact of papers produced by Sandra Tomek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra Tomek. The network helps show where Sandra Tomek may publish in the future.
Co-authors
The 25 scholars most cited alongside Sandra Tomek, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2007 | 7 | |
| 2 | N33 (TUSC3) promoter hypermethylation in serum of prostate cancer patients | 2006 | 2 |
| 3 | 2006 | 87 | |
| 4 | 2005 | 18 | |
| 5 | 2005 | 122 | |
| 6 | Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer. | 2004 | 25 |
| 7 | 2004 | 50 | |
| 8 | 2004 | 56 | |
| 9 | 2004 | 118 | |
| 10 | 2003 | 15 | |
| 11 | Recurrent malignant Triton tumour: first report on a long time survivor. | 2003 | 19 |
| 12 | 2002 | 8 | |
| 13 | Correlation of clinical outcome with p53 and p21 status in patients with advanced transitional-cell carcinoma treated with paclitaxel and carboplatin. | 2002 | 4 |
| 14 | 2001 | 21 | |
| 15 | 2000 | 9 | |
| 16 | 2000 | 28 | |
| 17 | 2000 | 10 |
About Sandra Tomek
Sandra Tomek is a scholar working on Oncology, Cancer Research, Immunology and Allergy, Neurology and Pulmonary and Respiratory Medicine, having authored 17 papers that have together received 599 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (4 papers), HER2/EGFR in Cancer Research (4 papers), Cell death mechanisms and regulation (3 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (2 papers), Pleural and Pulmonary Diseases (2 papers), Epigenetics and DNA Methylation (2 papers), Neuroblastoma Research and Treatments (2 papers) and Prostate Cancer Diagnosis and Treatment (2 papers). The work is most often cited by research in Oncology (263 citations), Cancer Research (113 citations), Radiology, Nuclear Medicine and Imaging (171 citations), Pulmonary and Respiratory Medicine (189 citations) and Immunology and Allergy (30 citations). Sandra Tomek has collaborated with scholars based in Austria and Germany. Frequent co-authors include Christoph Zielinski, Christian Manegold, Michael Krainer, Peter Horak, Dietmar Pils, Wolfgang J. Köstler, Ingrid Pribill, Günther Steger, Christoph Wiltschke and Max Roessler. Their work appears in journals such as Anti-Cancer Drugs, Gynecologic Oncology, Molecular Cancer Research, Clinical Cancer Research and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.